【摘要】：目的:觀察中成藥心脈康片對(duì)冠心病介入治療術(shù)后炎癥因子水平的影響,探討其治療介入治療術(shù)后冠心病可能的作用機(jī)制,從而為中西藥聯(lián)合治療介入治療術(shù)后冠心病提供新的思路和方法。方法:將采取支架植入術(shù)治療的冠心病患者60例納入研究,隨機(jī)分為治療組和對(duì)照組,每組各30例,對(duì)照組給予西藥常規(guī)治療,治療組在西藥基礎(chǔ)上加用心脈康片,檢測(cè)兩組患者支架植入術(shù)前6小時(shí)、術(shù)后12小時(shí)、治療1個(gè)月后血清超敏C反應(yīng)蛋白、白細(xì)胞介素-6、腫瘤壞死因子-α的水平,并進(jìn)行比較,探討介入治療操作對(duì)炎癥反應(yīng)的影響以及心脈康片對(duì)介入治療術(shù)后炎癥反應(yīng)的抑制作用。結(jié)果:(1)將兩組術(shù)后12h炎癥因子與術(shù)前6h比較,發(fā)現(xiàn)術(shù)后三種炎癥因子水平均明顯升高(表5,表6,表7)。(2)將治療1個(gè)月后兩組炎癥因子水平與術(shù)前6h比較,發(fā)現(xiàn)治療結(jié)束時(shí)兩組患者三種炎癥因子水平均明顯下降(表8,表9,表10)。(3)對(duì)比治療組和對(duì)照組治療1個(gè)月后血清炎癥因子下降的幅度,治療組hs-CRP、IL-6較對(duì)照組下降更為明顯,差異有統(tǒng)計(jì)學(xué)意義。而兩組TNF-α下降程度無(wú)顯著差異(表11)。結(jié)論:冠心病介入治療術(shù)后的藥物治療方案均具有一定抗炎作用,這可能是其實(shí)現(xiàn)預(yù)防血管病變進(jìn)展及再狹窄發(fā)生的作用機(jī)制之一。而心脈康片聯(lián)合西藥治療則具有更強(qiáng)的抗炎效果,因此中成藥心脈康片應(yīng)用于冠心病介入治療術(shù)后具有可行性,且能夠給病人帶來(lái)獲益。
[Abstract]:Objective: to observe the effect of Xinmai Kang tablet, a traditional Chinese patent medicine, on the level of inflammatory factors after interventional therapy of coronary heart disease (CHD), and to explore the possible mechanism of its effect on coronary heart disease after interventional therapy. Therefore, it provides a new way of thinking and method for coronary heart disease after interventional therapy with traditional Chinese medicine and western medicine. Methods: sixty patients with coronary heart disease treated by stent implantation were randomly divided into treatment group (n = 30) and control group (n = 30). The control group was treated with routine western medicine, and the treatment group was treated with Xinmai Kang tablet on the basis of western medicine. The serum levels of serum hypersensitive C-reactive protein, interleukin-6, tumor necrosis factor- 偽 were measured 6 hours before stent implantation and 12 hours after stent implantation in both groups. To investigate the effect of interventional therapy on inflammatory reaction and the inhibitory effect of Xinmaikang tablet on inflammatory response after interventional therapy. Results: (1) the levels of inflammatory cytokines in the two groups were significantly increased (table 5, table 6, and table 7). (2) at 12 hours after operation compared with 6 hours before operation (Table 5, Table 6, and Table 7). (2). The levels of inflammatory cytokines in the two groups were compared with those in 6 hours preoperatively after one month of treatment. It was found that at the end of treatment, the levels of three kinds of inflammatory factors in both groups were significantly decreased (table 8, table 9, table 10). (3). The levels of serum inflammatory factors in the treatment group and the control group were significantly decreased after one month of treatment. The hs-CRP, in the treatment group was significantly lower than that in the control group. The decrease of IL-6 was more obvious than that of the control group, and the difference was statistically significant. There was no significant difference in the degree of TNF- 偽 decrease between the two groups (Table 11). Conclusion: the drug therapy after coronary intervention therapy has some anti-inflammatory effect, which may be one of the mechanisms to prevent the progression and restenosis of coronary artery disease. Xinmaikang tablet combined with western medicine has stronger anti-inflammatory effect, so it is feasible to apply Xinmai Kang tablet to coronary heart disease intervention therapy, and can benefit patients.
【學(xué)位授予單位】：廣州中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R541.4

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陳偉偉;高潤(rùn)霖;劉力生;朱曼璐;王文;王擁軍;吳兆蘇;李惠君;顧東風(fēng);楊躍進(jìn);鄭哲;蔣立新;胡盛壽;;《中國(guó)心血管病報(bào)告2015》概要[J];中國(guó)循環(huán)雜志;2016年06期

2 韓雅玲;;2016中國(guó)經(jīng)皮冠狀動(dòng)脈介入治療指南解讀[J];臨床軍醫(yī)雜志;2016年05期

3 盛文芳;洪斌;;不同劑量氯吡格雷對(duì)ACS患者PCI術(shù)后炎癥因子的影響[J];臨床和實(shí)驗(yàn)醫(yī)學(xué)雜志;2015年24期

4 高潤(rùn)霖;;經(jīng)皮冠狀動(dòng)脈介入治療發(fā)展歷程[J];中國(guó)醫(yī)學(xué)前沿雜志(電子版);2015年01期

5 章春艷;章爽;;急性冠脈綜合征患者炎癥因子IL-6、IL-8、IL-1β、TNF-α及hs-CRP水平檢測(cè)[J];心腦血管病防治;2014年06期

6 于輝;趙陽(yáng);;急性冠狀動(dòng)脈綜合征患者血清中炎癥因子檢測(cè)及其臨床價(jià)值[J];中國(guó)現(xiàn)代醫(yī)學(xué)雜志;2014年17期

7 李云松;畢偉;張彥榮;田錦林;王偉;郭躍輝;;高敏C反應(yīng)蛋白、白細(xì)胞介素6水平對(duì)股乆動(dòng)脈支架植入術(shù)后再狹窄的影響[J];中國(guó)普通外科雜志;2014年06期

8 張璐;孫晴;郭書(shū)文;鄭敏;鄭乘龍;張闊;范盎然;齊欣;;調(diào)脂通脈中藥對(duì)動(dòng)脈粥樣硬化兔模型炎癥因子表達(dá)的影響[J];北京中醫(yī)藥大學(xué)學(xué)報(bào);2014年03期

9 楊蕾;王麗娟;;冠狀動(dòng)脈支架內(nèi)再狹窄的相關(guān)性因素分析[J];中國(guó)動(dòng)脈硬化雜志;2013年05期

10 李巍;黃嵐;;PCI術(shù)后再狹窄的病理生理及其危險(xiǎn)因素[J];中國(guó)動(dòng)脈硬化雜志;2013年04期

，

本文編號(hào)：2305549